TSX gains after CPI shows US inflation rose 3%
Arcellx (NASDAQ:ACLX), a $4.35 billion biotech company showing strong momentum with double-digit returns over the past three months, reported a significant insider transaction. Chief Medical Officer Christopher Heery sold 12,396 shares of common stock on September 26, 2025, for approximately $993,155. The shares were sold at a weighted average price of $80.119, in a price range of $80.00 to $80.41.
Following the transaction, Heery directly owns 21,731 shares of Arcellx . The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 23, 2025. According to InvestingPro data, analysts maintain a strong buy consensus on the stock, with price targets ranging from $100 to $134. For deeper insights into Arcellx’s financial health and growth prospects, including 13 additional ProTips and comprehensive analysis, check out the full research report on InvestingPro.
In other recent news, Arcellx Inc. has been the focus of several analyst updates. Scotiabank raised its price target for Arcellx to $133 from $93, maintaining a Sector Outperform rating. This adjustment follows the departure of Vinay Prasad, head of the FDA’s Center for Biologics Evaluation and Research, which Scotiabank believes removes a regulatory hurdle for the company. Additionally, Piper Sandler has reiterated its Overweight rating with a $115 price target, indicating continued confidence in Arcellx. This comes amid investor attention on the safety profiles of Arcellx’s anito-cel therapy compared to Johnson & Johnson’s Carvykti. These recent developments reflect ongoing interest and analysis from the investment community regarding Arcellx’s position in the competitive cell therapy landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.